Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

<h4>Background</h4>Circulating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value...

Full description

Bibliographic Details
Main Authors: Josep Lupón, Evelyn Santiago-Vacas, Germán Cediel, Pau Codina, Mar Domingo, Elena Revuelta-López, Elisabet Zamora, Giosafat Spitaleri, Javier Santesmases, Julio Núñez, Antoni Bayes-Genis
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0249674

Internet

https://doi.org/10.1371/journal.pone.0249674

Similar Items